Biogen Inc. (BIIB) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Drug Manufacturers - General
Biogen Inc. (BIIB) Profile & Business Summary
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Key Information
| Ticker | BIIB |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://www.biogen.com |
Market Trend Overview for BIIB
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-03-25 (ET)
As of 2026-03-25, BIIB is moving sideways with low volatility. Over the longer term, the trend remains bullish.
BIIB last closed at 189.18. The price is about 0.3 ATR above its recent average price (187.64), and the market is currently in a sideways market with low volatility. Price at 189.18 is moving between minor support near 187.20 and minor resistance near 190.20. Direction remains unclear. View Support & Resistance from Options
Price is moving in a tight range. This often leads to a stronger move once the range breaks, increasing one-sided risk.
Trend score: 40 out of 100. Overall alignment is unclear. The market is currently in a sideways phase with tightening price movement. The longer-term trend is still positive, but short-term signals are not yet confirming it.
A key downside level is near 173.52. If price falls below this area, the current upward trend would likely weaken or break.
On 2026-03-02, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-03-09] Price moved quickly and looked strong, but participation was limited.
Recent price action shows orderly upward progression with no major deterioration in bar-level efficiency. Structural conditions remain broadly constructive.
Closing activity showed limited conviction and did not suggest strong overnight positioning.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This reading is based on the last 20 trading days of 15-minute price, volume, and VWAP data. Price is modestly above the recent estimated cost basis of 185.37, so the recent structure is still on the firmer side. Price is above the main cost band (183.18 to 184.86), and about 90% of recent positioning is already in profit. That supports trend strength, but it also raises the chance of profit-taking if momentum cools. The nearby support area sits around 188.80 to 189.02, and it looks fairly solid right now. From a trading point of view, the trend still has support. The main question is whether pullbacks stay orderly above or near 188.80 to 189.02.
Short Interest & Covering Risk for BIIB
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is within its typical range, with no clear imbalance between buyers and sellers. (Historical percentile: 50%)
Structure Analysis
BIIB Short positioning is starting to look crowded. Current days to cover is 4.6 trading days, meaning short positions would unwind somewhat slower than average. Short covering could add extra momentum to price moves. Early signs of positioning pressure are emerging (Fragility Score 42/100, DTC percentile 100%) as price consolidates near recent highs (20D return -0.8%) and liquidity contracting meaningfully (volume -49%). Short positioning is at extreme historical levels.
Risk Summary
Some early warning signs are emerging. Price strength remains intact, but underlying support may be starting to weaken.This indicator is intended as a risk filter, not a directional signal. A High or Extreme reading does not predict an immediate move, but suggests that if prices weaken, downside reactions may be more pronounced.
Why Price Reactions May Be Stronger?
Days-to-Cover is elevated versus its own history, but absolute short interest remains moderate. Average trading volume is weakening, indicating contracting liquidity. Price action is compressing (range is tightening), which can make breaks more sensitive. Price is consolidating near highs with a weak upward bias; surface strength may mask a more fragile structure. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. High-level consolidation and compression suggest a fragile upside structure. As a result, similar news or market events could lead to price moves about 2× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-02-27 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.